Dr. Piyush K. Agarwal

Urology
5841 S Maryland Ave, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Piyush Agarwal is a Urologist in Chicago, Illinois. Dr. Agarwal is rated as an Experienced provider by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Prostatectomy. Dr. Agarwal is currently accepting new patients.

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in IL
Hospital Affiliations
The University Of Chicago Medical Center
Uchicago Medicine Northwest Indiana
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens From Healthy Volunteers and Urothelial Cancer Patients
Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens From Healthy Volunteers and Urothelial Cancer Patients
Enrollment Status: Recruiting
Publish Date: November 21, 2025
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Diagnostic test, Drug, Procedure
Study Drugs: Durvalumab, Vicinum
Study Phase: Phase 1
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
View 4 Less Clinical Trials

142 Total Publications

Transfer and beyond: emerging strategies and trends in two-dimensional material device fabrication.
Transfer and beyond: emerging strategies and trends in two-dimensional material device fabrication.
Journal: Chemical Society reviews
Published: January 06, 2026
Similar Doctors
Gopal N. Gupta
Experienced in Von Hippel-Lindau (VHL) Syndrome
Dr. Gopal N. Gupta
Urology
Experienced in Von Hippel-Lindau (VHL) Syndrome
Dr. Gopal N. Gupta
Urology

Loyola University Medical Center

719 W N Ave, 
Melrose Park, IL 
 (15.0 miles away)
708-538-6773
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Gopal Gupta is a Urologist in Melrose Park, Illinois. Dr. Gupta is rated as an Elite provider by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Prostate Cancer, Nephrectomy, and Cystectomy. Dr. Gupta is currently accepting new patients.

Experienced in Von Hippel-Lindau (VHL) Syndrome
Dr. Marcus L. Quek
Urology
Experienced in Von Hippel-Lindau (VHL) Syndrome
Dr. Marcus L. Quek
Urology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (12.9 miles away)
708-216-9000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Marcus Quek is a Urologist in Maywood, Illinois. Dr. Quek is rated as an Elite provider by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Bladder Cancer, Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Cystectomy. Dr. Quek is currently accepting new patients.

Experienced in Von Hippel-Lindau (VHL) Syndrome
Dr. James J. Siegert
Urology
Experienced in Von Hippel-Lindau (VHL) Syndrome
Dr. James J. Siegert
Urology

Specialty Physicians Of Illinois LLC

3700 W 203rd St, 
Olympia Fields, IL 
 (19.3 miles away)
708-679-2580
Languages Spoken:
English
See accepted insurances

James Siegert is a Urologist in Olympia Fields, Illinois. Dr. Siegert is rated as a Distinguished provider by MediFind in the treatment of Von Hippel-Lindau (VHL) Syndrome. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Enlarged Prostate (BPH), Ureteroscopy, and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Agarwal's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile